Revenio Capital

Revenio Capital operates as the private equity and corporate-development arm of Revenio Group. It identifies and acquires eye-diagnostics companies that are then integrated into the parent’s product portfolio. It is not a separate third-party fund manager.

There is no public evidence that Revenio Capital raises outside capital or runs a multi-investor fund structure. Its deals appear funded through the balance sheet and free cash flow of the publicly traded Revenio Group.

The firm targets early-stage, seed, and start-up companies in the medical-technology space, specifically within the eye-care and ophthalmic diagnostics subsectors. Its primary activity is control acquisitions rather than passive venture investments.

Revenio Capital sources acquisition targets that complement Revenio Group’s existing diagnostics and software workflow business under the iCare and Visionix brands. The emphasis is on device and imaging companies that can be folded into the group’s European and global distribution network.

The firm is exclusively focused on eye-health technology, including tonometry, OCT imaging, perimetry, refraction devices, and clinical software. It does not appear to invest outside ophthalmology or vision care.